Global PDGFR Inhibitors Market, Drug Sales & Clinical Trials Insight 2026 Report Analysis & Data Highlights:
- Research Methodology
- Global & Regional Market Analysis
- Global PDGFR Inhibitors Market Opportunity Assessment: > USD 4 Billion
- Market & Drug Sales Insight 2020 Till 2026
- Approved Drug In Market: 2 (Qinlock & Ayvakit)
- Approved PGDFR Drug Patent, Price & Sales insight 2020 Till 2026
- Future market Assessment By Indication & Region Till 2026
- Ongoing Clinical Trials Assessment by Status, Phase & Region
- Key Market Dynamics
- Competitor Landscape
Platelet derived growth factor receptor (PDGFR) are tyrosine kinase receptor which are expressed on the surface of normal cells and have critical role in maintaining the normal functions of body. However, studies have demonstrated that dysregulation of the PDGFR signaling pathway is associated with several pathological conditions including cancer, fibrosis, asthma, neurological conditions and atherosclerosis. Thus, PDGFR appeared to be potential therapeutic target for management of these diseases.
Since its identification, scientists have done considerable efforts for the development of novel drugs which can inhibit the activity of PDGFR. As of now, two PDGFR inhibitors have been approved by the regulatory bodies which are indicated for the management of gastrointestinal stromal tumors (GIST) and mastocytosis. Larturvo developed by Eli Lilly was the first PDGFR targeting antibody was the first PDGFR inhibitor approved. However in 2019, the drug was withdrawn from market as it failed the phase-III trial in which it was unable to improve the overall survival. Furthermore, it demonstrated embryo fetal toxicity in animal models as it cause malformations and skeletal variations.
Later, Ayvakit developed by Blueprint Medicines and Qinlock developed by Deciphera Pharmaceuticals have gained entry into the market. It’s been only one year since their introduction into the market, and these drugs have shown high adoption rates which can be justified by the robust sales. In addition to these, extensive research and development activities in this sector has further led to the development of robust pipeline of PDGFR targeting drugs including Crenolanib, Tovetumab, Seralutinib, ARRY-768, CP-673451, and MTLH001. These drugs have shown promising anti-tumor activity and are mostly present in phase-I/II clinical trial, suggesting that they will enter the market in next 3-5 years. The rapid influx of these potential PDGFR inhibitor will drive the growth of market.
In addition to gastrointestinal stromal tumors, researchers are also validating the role of PDGFR inhibitors in targeting other cancers including breast cancer, non-small cell lung cancer, acute myeloid leukemia, glioma, colorectal cancer, and others. Moreover, the coming years will see a dominance of combinational therapy in the market owing to its enhanced efficacy in targeting the disease. For instance, Larturvo despite its withdrawal is under investigation in combination with Trabectedin, Pembrolizumab, Ifosfamide, Doxorubicin, Gemcitabine, Vincristine etc. Therefore, it is expected that Lartruvo will return to the market in the form of combinational agent in near future.
During the forecast period, it is expected that global PDGFR inhibitors market will witness high growth rates. The key players in the market are increasingly partnering or collaborating with technologies companies to integrate advanced technologies which will boost the growth of market. The major companies investing in the growth of market are Gilead Sciences, Bayer, Pfizer, Arog Pharmaceutical, Tyrogenex, and AstraZeneca. The huge investment made by these companies and extensive efforts by scientists will propel the growth of market for next few years.
Regionally, US are expected to dominate the market owing to an increased prevalence of cancer and increased awareness about the therapy. Moreover, the robust pipeline of drugs which are expected approval will also boost the growth of market in the region. Asia-Pacific represents lucrative opportunity for key players operating in the market, owing to increase in population, coupled with high growing geriatric population and growth in awareness among healthcare entities and patients pertaining to potential of these therapies in chronic disease management. In addition, rise in healthcare expenditure and developing guidelines are expected to propel the market growth in the region.